Tango Therapeutics, Inc.TNGX
Price (close)
$24.63
Market cap
$4.2B
P/E
—
Revenue (TTM)
$53.8M
Net income
-$123.7M
Dividend yield
—
1-year total return
209.0%
Net margin
-229.9%
Revenue growth
121.5%
Debt / equity
—
What Tango Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.7M | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Net income | -$52.0M | -$58.2M | -$108.2M | -$101.7M | -$130.3M | -$101.6M |
| Free cash flow | $69.0M | -$61.4M | -$116.8M | -$119.5M | -$132.3M | -$139.9M |
More on TNGX.
- Tango Therapeutics, Inc. summary
- Tango Therapeutics, Inc. financial statements
- Tango Therapeutics, Inc. key metrics
- Tango Therapeutics, Inc. health scores and style box
- Tango Therapeutics, Inc. earnings
- Tango Therapeutics, Inc. dividends
- Tango Therapeutics, Inc. valuation
- Tango Therapeutics, Inc. ownership and insiders
- Tango Therapeutics, Inc. peers
Figures from Tango Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.